Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells $43,381.97 in Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson sold 6,583 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total value of $43,381.97. Following the completion of the sale, the chief financial officer now owns 93,546 shares of the company’s stock, valued at approximately $616,468.14. This trade represents a 6.57 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Molly Henderson also recently made the following trade(s):

• On Thursday, December 19th, Molly Henderson sold 1,291 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $8.00, for a total value of $10,328.00.

Phathom Pharmaceuticals Trading Down 3.8 %

PHAT stock opened at $6.90 on Friday. The firm has a 50 day simple moving average of $8.00 and a 200-day simple moving average of $12.47. The company has a market capitalization of $471.80 million, a P/E ratio of -1.21 and a beta of 0.56. Phathom Pharmaceuticals, Inc. has a twelve month low of $6.07 and a twelve month high of $19.71.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.57) by $0.25. The company had revenue of $16.35 million for the quarter, compared to analyst estimates of $12.54 million. During the same period in the prior year, the business earned ($0.76) earnings per share. On average, research analysts predict that Phathom Pharmaceuticals, Inc. will post -4.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on PHAT shares. HC Wainwright reissued a “buy” rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a research report on Thursday, December 12th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Friday, January 10th.

Institutional Trading of Phathom Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of PHAT. Huntington National Bank lifted its holdings in Phathom Pharmaceuticals by 62.2% during the 3rd quarter. Huntington National Bank now owns 1,471 shares of the company’s stock worth $27,000 after buying an additional 564 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Phathom Pharmaceuticals by 41.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock worth $43,000 after purchasing an additional 722 shares during the last quarter. US Bancorp DE boosted its holdings in Phathom Pharmaceuticals by 28.6% in the third quarter. US Bancorp DE now owns 5,248 shares of the company’s stock worth $95,000 after purchasing an additional 1,166 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Phathom Pharmaceuticals by 10.6% in the second quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company’s stock worth $144,000 after purchasing an additional 1,339 shares during the period. Finally, Quest Partners LLC bought a new stake in Phathom Pharmaceuticals during the third quarter valued at $197,000. 99.01% of the stock is owned by institutional investors.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.